Canadian cardiovascular drug development company Milestone Pharmaceuticals has secured $55m through a series C funding round led by Novo Holdings.
The company plans to use the funds to progress the development of its lead product etripamil into Phase 3. The funds will also be used towards marketing and increasing headcount.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Homology Medicines has secured $83.5m through a series B funding round led by Deerfield Management Company.
The US-based genetic medicines company plans to use the funds to advance the development of its lead candidate AMEnDR™, which is currently in the pre-clinical stage.
Ultragenyx Pharmaceutical plans to issue common stock shares through a public offering to raise up to $150m.
The US-based clinical-stage biopharmaceutical company plans to use the funds to advance the development of its clinical and pre-clinical products as well as towards working capital and general corporate purposes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPreciThera has secured C$36m ($28.8m) through a financing round led by Arix Bioscience.
Based in Canada, PreciThera is a biotechnology company focused on the development of orphan bone diseases. The company plans to use the funds to progress its drug candidates into the clinical stage.
